Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

PRLD Prelude Therapeutics Incorporated
$4.45 -3.05% -0.14
Notify me if price changes either direction
Interactive Brokers Logotype

Buy PRLD stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades
Loading

Key Stats

Market cap. 366.3M
Enterprise value 338.6M
Trailing PE -3.4496124031008
Forward PE -6.1200004
PEG Ratio 0.052383003158197
Enterprise to EBITDA -5.249
Enterprise to revenue 15.102
Price to book MRQ 3.5334873
Price to sales TTM 16.335089

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 22.4M
EBITDA -64510000
Diluted EPS TTM -0.73
Total Cash (MRQ) 151.8M
Current ratio (MRQ) 4.072
Operating Cash Flow (TTM) -33255000

PRLD trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent PRLD News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.